Kelsey Ohman1, Bridgette Kram2, Jennifer Schultheis2, Jana Sigmon3, Safa Kaleem4, Zidanyue Yang5, Hui-Jie Lee5, Cory Vatsaas6, Jordan Komisarow7. 1. Department of Pharmacy, Duke University Hospital, Durham, NC, USA. Kelsey.ohman@duke.edu. 2. Department of Pharmacy, Duke University Hospital, Durham, NC, USA. 3. Department of Pharmacy, Harris Health System, Harris County, Houston, TX, USA. 4. Department of Neurology, NewYork-Presbyterian Weill Cornell Medical Center, New York, NY, USA. 5. Department of Biostatistics and Bioinformatics, Duke University Hospital, Durham, NC, USA. 6. Department of Trauma and Critical Care Surgery, Duke University Hospital, Durham, NC, USA. 7. Department of Neurosurgery, Duke University Hospital, Durham, NC, USA.
Abstract
BACKGROUND: Although levetiracetam has been increasingly used as an alternative to phenytoin for early posttraumatic seizure prophylaxis following traumatic brain injury (TBI), an optimal dosing strategy has not been elucidated. The objective of this study is to determine whether different dosing strategies of levetiracetam are associated with the incidence of early posttraumatic seizures when used as prophylaxis following TBI. METHODS: This retrospective single-center cohort study included admitted patients ≥ 18 years of age with a diagnosis of TBI and receiving levetiracetam for early posttraumatic seizure prophylaxis between July 1, 2013, and September 1, 2019. The primary outcome of this study was to evaluate three different dosing strategies of levetiracetam (≤ 1000 mg/day, 1500 mg/day, and ≥ 2000 mg/day) and associated rates of early posttraumatic seizures. Secondary outcomes were to summarize absolute total daily maintenance doses of levetiracetam among patients who experienced early posttraumatic seizures compared with those who did not, to determine the impact of three different dosing strategies on hospital length of stay and in-hospital mortality, and to assess patient-specific variables on the occurrence of posttraumatic seizures. Overlap propensity score weighting was used to address the potential for confounding. RESULTS: Of the 1287 patients who received levetiracetam for early posttraumatic seizure prophylaxis during the study time frame, 866 patients met eligibility criteria and were included in the study cohort (289 patients in the ≤ 1000 mg/day group, 137 patients in the 1500 mg/day group, and 440 patients in the ≥ 2000 mg/day group). After weighting, the cumulative incidence of early posttraumatic seizure was 2.9% in the ≤ 1000 mg/day group, 8.8% in the 1500 mg/day group, and 9% in the ≥ 2000 mg/day group. The 1500 mg/day and ≥ 2000 mg/day levetiracetam groups had a 209% and 216% increase in the subdistribution hazard of early posttraumatic seizures compared with the ≤ 1000 mg/day levetiracetam group, respectively, but these differences were not statistically significant. CONCLUSIONS: In conclusion, the results of this study demonstrate no statistically significant difference in the cumulative incidence of early posttraumatic seizures within 7 days of TBI between three different levetiracetam dosing strategies. After weighting, the ≤ 1000 mg/day levetiracetam group had the lowest rates of early posttraumatic seizures, death without seizure, and in-hospital mortality.
BACKGROUND: Although levetiracetam has been increasingly used as an alternative to phenytoin for early posttraumatic seizure prophylaxis following traumatic brain injury (TBI), an optimal dosing strategy has not been elucidated. The objective of this study is to determine whether different dosing strategies of levetiracetam are associated with the incidence of early posttraumatic seizures when used as prophylaxis following TBI. METHODS: This retrospective single-center cohort study included admitted patients ≥ 18 years of age with a diagnosis of TBI and receiving levetiracetam for early posttraumatic seizure prophylaxis between July 1, 2013, and September 1, 2019. The primary outcome of this study was to evaluate three different dosing strategies of levetiracetam (≤ 1000 mg/day, 1500 mg/day, and ≥ 2000 mg/day) and associated rates of early posttraumatic seizures. Secondary outcomes were to summarize absolute total daily maintenance doses of levetiracetam among patients who experienced early posttraumatic seizures compared with those who did not, to determine the impact of three different dosing strategies on hospital length of stay and in-hospital mortality, and to assess patient-specific variables on the occurrence of posttraumatic seizures. Overlap propensity score weighting was used to address the potential for confounding. RESULTS: Of the 1287 patients who received levetiracetam for early posttraumatic seizure prophylaxis during the study time frame, 866 patients met eligibility criteria and were included in the study cohort (289 patients in the ≤ 1000 mg/day group, 137 patients in the 1500 mg/day group, and 440 patients in the ≥ 2000 mg/day group). After weighting, the cumulative incidence of early posttraumatic seizure was 2.9% in the ≤ 1000 mg/day group, 8.8% in the 1500 mg/day group, and 9% in the ≥ 2000 mg/day group. The 1500 mg/day and ≥ 2000 mg/day levetiracetam groups had a 209% and 216% increase in the subdistribution hazard of early posttraumatic seizures compared with the ≤ 1000 mg/day levetiracetam group, respectively, but these differences were not statistically significant. CONCLUSIONS: In conclusion, the results of this study demonstrate no statistically significant difference in the cumulative incidence of early posttraumatic seizures within 7 days of TBI between three different levetiracetam dosing strategies. After weighting, the ≤ 1000 mg/day levetiracetam group had the lowest rates of early posttraumatic seizures, death without seizure, and in-hospital mortality.
Authors: Nancy Carney; Annette M Totten; Cindy O'Reilly; Jamie S Ullman; Gregory W J Hawryluk; Michael J Bell; Susan L Bratton; Randall Chesnut; Odette A Harris; Niranjan Kissoon; Andres M Rubiano; Lori Shutter; Robert C Tasker; Monica S Vavilala; Jack Wilberger; David W Wright; Jamshid Ghajar Journal: Neurosurgery Date: 2017-01-01 Impact factor: 4.654
Authors: Nickalus R Khan; Matthew A VanLandingham; Tamara M Fierst; Caroline Hymel; Kathryn Hoes; Linton T Evans; Rory Mayer; Fred Barker; Paul Klimo Journal: Neurosurgery Date: 2016-12 Impact factor: 4.654
Authors: Ricky Wat; Marco Mammi; Jose Paredes; Jordan Haines; Mohammed Alasmari; Aaron Liew; Victor M Lu; Omar Arnaout; Timothy R Smith; William B Gormley; Linda S Aglio; Rania A Mekary; Hasan Zaidi Journal: World Neurosurg Date: 2018-11-20 Impact factor: 2.104
Authors: Kenji Inaba; Jay Menaker; Bernardino C Branco; Jonathan Gooch; Obi T Okoye; Joe Herrold; Thomas M Scalea; Joseph Dubose; Demetrios Demetriades Journal: J Trauma Acute Care Surg Date: 2013-03 Impact factor: 3.313
Authors: Kristen E Jones; Ava M Puccio; Kathy J Harshman; Bonnie Falcione; Neal Benedict; Brian T Jankowitz; Martina Stippler; Michael Fischer; Erin K Sauber-Schatz; Anthony Fabio; Joseph M Darby; David O Okonkwo Journal: Neurosurg Focus Date: 2008-10 Impact factor: 4.047
Authors: Pamela L Ferguson; Gigi M Smith; Braxton B Wannamaker; David J Thurman; E Elisabeth Pickelsimer; Anbesaw W Selassie Journal: Epilepsia Date: 2009-10-20 Impact factor: 5.864
Authors: Christopher D Wilson; Josh D Burks; Richard B Rodgers; Robert M Evans; Adewale A Bakare; Sam Safavi-Abbasi Journal: World Neurosurg Date: 2017-12-02 Impact factor: 2.104